GPR139 GPCR agonist

oral (40-160 mg QD) Ph. II for schizophrenia

625k-cmpd cell-based screen (21 nM hit) + opt

Journal of Medicinal Chemistry

Takeda, San Diego, US

The Takeda GPR139 agonist, TAK-041, is a CNS-penetrant GPCR agonist being explored for schizophrenia symptoms and is an interesting example of a triazinone-containing clinical candidate. GPR139 is an orphan GPCR…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks